SCHILKE TOBIN (CFO) received a stock award from REVANCE THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/2/2024ACC: 0001479290-24-000015
Officer· CFO
Since Nov 2018
+241.67K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
241.67K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+96.67K
Price / share
—
Trade value
—
% of position
105.4%
1/31/2024
91.73K→188.40K
Total
Net shares
+96.67K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/31/2024 | A · Award | +96.67K | — | — | 105.4% | 91.73K | 188.40K |
| Total | +96.67K | $0.00 | ||||||
Derivative Transactions1
Performance Stock Units
Direct
Converts to
Common Stock
145K shares
Shares
+145K
Strike price
Held after
145K
Exercisable
—
1/31/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Performance Stock Units Direct | Common Stock145K shares | 1/31/2024 | A · Award | +145K | — | 145K |